Bitolterol
Tornalate (bitolterol) is a small molecule pharmaceutical. Bitolterol was first approved as Tornalate on 1984-12-28. It is used to treat asthma and bronchial spasm in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| asthma | EFO_0000270 | D001249 | J45 |
| bronchial spasm | — | D001986 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
77 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 3 | 2 | 6 | 5 | 15 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | 11 | 2 | 14 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | 3 | 2 | 6 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | 1 | 2 | 1 | 5 |
| Coronary artery disease | D003324 | I25.1 | 1 | 1 | 1 | 3 | — | 5 | |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | 2 | — | 2 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | 2 | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | 1 | 2 |
| St elevation myocardial infarction | D000072657 | — | — | — | 2 | — | 2 | ||
| Non-st elevated myocardial infarction | D000072658 | — | — | — | 2 | — | 2 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | 1 | — | — | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 2 | — | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 1 | — | — | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | 1 | — | — | 1 | |
| Duchenne muscular dystrophy | D020388 | — | 1 | 1 | — | — | 1 | ||
| Dilated cardiomyopathy | D002311 | EFO_0000407 | I42.0 | — | 1 | 1 | — | — | 1 |
| Chagas cardiomyopathy | D002598 | EFO_0005529 | — | — | 1 | — | — | 1 | |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | 1 | — | — | 1 |
| Essential hypertension | D000075222 | I10 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 2 | — | — | — | 2 | |
| Familial primary pulmonary hypertension | D065627 | I27.0 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
| Heart rate | D006339 | EFO_0004326 | 1 | — | — | — | — | 1 | |
| Fasting | D005215 | EFO_0002756 | 1 | — | — | — | — | 1 | |
| Abdominal aortic aneurysm | D017544 | EFO_0004214 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | 1 | 1 | |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | 1 | 1 | |
| Patient participation | D010358 | — | — | — | — | 1 | 1 | ||
| Coronary disease | D003327 | — | — | — | — | 1 | 1 | ||
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | — | — | — | 1 | 1 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 1 | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BITOLTEROL |
| INN | bitolterol |
| Description | Bitolterol is the di-4-toluate ester of (+-)-N-tert-butylnoradrenaline (colterol). A pro-drug for colterol, a beta2-adrenergic receptor agonist, bitolterol is used as its methanesulfonate salt for relief of bronchospasm in conditions such as asthma, chronic bronchitis and emphysema. It has a role as a bronchodilator agent, an anti-asthmatic drug, a beta-adrenergic agonist and a prodrug. It is a member of ethanolamines, a carboxylic ester, a diester, a secondary amino compound and a secondary alcohol. |
| Classification | Small molecule |
| Drug class | bronchodilators (phenethylamine derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 30392-40-6 |
| RxCUI | 19499 |
| ChEMBL ID | CHEMBL1201295 |
| ChEBI ID | 3133 |
| PubChem CID | 35330 |
| DrugBank | DB00901 |
| UNII ID | 9KY0QXD6LI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 55 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
24,848 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more